Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment MonitoringPRNewsWire • 11/10/20
Natera, Inc. (NTRA) CEO Steve Chapman on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/08/20
International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin PregnanciesPRNewsWire • 10/30/20
Natera's Panorama® NIPT Receives Average Risk Coverage for an Additional 24 Million LivesPRNewsWire • 10/08/20
Natera Teams Up with the George Lopez Foundation on the #GLFTrickShot Kidney Disease Awareness ChallengePRNewsWire • 10/05/20
Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera™PRNewsWire • 10/02/20
Medicare Issues Draft Local Coverage Determination for Signatera™ in Immunotherapy Response MonitoringPRNewsWire • 09/24/20
Natera Launches Initiative to Transform the Management of Cancer Patients in Organ TransplantationPRNewsWire • 09/14/20
Natera's Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal CancerPRNewsWire • 09/11/20
Natera to Present at the Morgan Stanley 18th Annual Global Healthcare ConferencePRNewsWire • 09/10/20
Natera Receives Final Medicare Coverage for its Signatera™ MRD Test in Stage II-III Colorectal CancerPRNewsWire • 09/03/20
Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast CancerPRNewsWire • 08/27/20
